ANCA-associated Vasculitis — Research Summary
Printed from RareWays (rareways.com.au) on 11 June 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Integrative transcriptomic and machine learning analysis identifies PYCARD and IFI30 as immune-lysosomal biomarkers of ANCA-associated glomerulonephritis.
Bei Liyuan et al. — Renal failure (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41668326/
- 2.
Update on antineutrophil cytoplasmic antibody vasculitis: Erratum.
Mandel Dan A et al. — Current opinion in nephrology and hypertension (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41883005/
- 3.
New insights into clinical spectrum of antineutrophil cytoplasmic autoantibody associated disease.
Alba Marco A et al. — Current opinion in nephrology and hypertension (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41717852/
- 4.
Eosinophilic granulomatosis with polyangiitis: recent therapeutic advances.
Chiara Emanuele et al. — Current opinion in rheumatology (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41717826/
- 5.
Comment on "Interstitial Lung Disease in ANCA-Associated Vasculitis: A European Multicentre Study".
Iannone Claudia et al. — Arthritis & rheumatology (Hoboken, N.J.) (3 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41930630/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
Recruiting — Phase 2 — Alexion Pharmaceuticals, Inc.
https://clinicaltrials.gov/study/NCT07160608
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
ANCA-associated Vasculitis
ANCA-associated Vasculitis is a group of rare autoimmune diseases characterised by inflammation of small blood vessels, associated with antineutrophil cytoplasmic antibodies (ANCA). It primarily affects the kidneys and lungs and can be rapidly progressive. Without treatment it carries high mortality, but outcomes have improved substantially with immunosuppressive therapy and rituximab.
Most Recent Research
OBJECTIVES: ANCA-associated glomerulonephritis (ANCA-GN) is an immune-mediated kidney disease leading to acute or chronic renal failure. This study investigates the role of mitophagy-related genes in ANCA-GN, as mitochondrial dysfunction is closely linked to the pathogenesis of various kidney diseases. METHODS: This study analyzed transcriptomic data from GEO datasets (GSE104948 and GSE108109) to investigate mitophagy-related mechanisms in ANCA-GN. Methods included batch correction, consensus clustering (identifying two subtypes), weighted gene co-expression network analysis (WGCNA), differential expression screening, and machine learning (LASSO, random forest, SVM-RFE). A diagnostic nomogram was constructed and validated, and immune cell infiltration was profiled. RESULTS: Analyses revealed distinct activation of immune pathways, including complement and phagosome signaling, alongside abnormal infiltration of CD8+ T cells in ANCA-GN. Subtype-specific analysis identified 131 differentially expressed genes (DEGs), while 143 DEGs distinguished ANCA-GN from controls.Intersection analysis and machine learning prioritized two hub genes, PYCARD and IFI30, which exhibited strong diagnostic accuracy (AUC >0.9) and correlated with CD8+ T-cell infiltration. A nomogram model validated their clinical utility (AUC >0.9). Functional enrichment highlighted phagocytosis and immune signaling pathways. Immune profiling revealed significant upregulation of 20 immune cell types in ANCA-GN. CONCLUSIONS: These findings suggest that mitophagy-immune crosstalk drives ANCA-GN progression, with PYCARD and IFI30 as potential diagnostic biomarkers. This study provides mechanistic insights into ANCA-GN pathogenesis and proposes novel targets for clinical intervention.
Common Questions
What is ANCA-associated Vasculitis?
ANCA-associated Vasculitis is a group of rare autoimmune diseases characterised by inflammation of small blood vessels, associated with antineutrophil cytoplasmic antibodies (ANCA). It primarily affects the kidneys and lungs and can be rapidly progressive. Without treatment it carries high mortality, but outcomes have improved substantially with immunosuppressive therapy and rituximab.
How many clinical trials are available for ANCA-associated Vasculitis?
RareWays currently indexes 163 clinical trials for ANCA-associated Vasculitis, of which 63 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for ANCA-associated Vasculitis come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for ANCA-associated Vasculitis.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.